Amodiaquine
(Redirected from Amodiaquine hydrochloride)
Amodiaquine is a medication used to treat and prevent malaria. It is often used in combination with other antimalarial drugs, such as artesunate or sulfadoxine/pyrimethamine. Amodiaquine is a 4-aminoquinoline compound, similar to chloroquine, and it works by interfering with the growth of Plasmodium parasites in the red blood cells.
Medical Uses[edit | edit source]
Amodiaquine is primarily used for the treatment of uncomplicated malaria caused by Plasmodium falciparum and Plasmodium vivax. It is also used in malaria prophylaxis in areas where chloroquine resistance is prevalent. The drug is often administered as part of a combination therapy to reduce the risk of resistance development.
Mechanism of Action[edit | edit source]
Amodiaquine works by inhibiting the heme polymerase activity in the Plasmodium parasites. This inhibition leads to the accumulation of toxic heme within the parasite, ultimately causing its death. The drug is effective against the erythrocytic stage of the parasite's life cycle.
Side Effects[edit | edit source]
Common side effects of amodiaquine include nausea, vomiting, abdominal pain, and headache. Serious side effects can include hepatotoxicity, agranulocytosis, and aplastic anemia. Due to these potential risks, the use of amodiaquine is generally limited to areas where the benefits outweigh the risks.
Pharmacokinetics[edit | edit source]
Amodiaquine is well absorbed from the gastrointestinal tract and is metabolized in the liver to its active metabolite, desethylamodiaquine. The drug and its metabolites are excreted primarily in the urine.
History[edit | edit source]
Amodiaquine was first synthesized in the 1940s and has been used extensively in the treatment of malaria. However, its use declined due to the emergence of drug-resistant strains of Plasmodium falciparum and concerns over its safety profile. In recent years, it has seen a resurgence in use as part of combination therapies.
Research[edit | edit source]
Ongoing research is focused on improving the efficacy and safety of amodiaquine, as well as developing new combination therapies to combat drug-resistant malaria strains.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
